Chronic myelogenous leukemia

Laboratory diagnosis and monitoring

Y. Lynn Wang, A. Bagg, Warren Pear, Peter C. Nowell, Jay Hess

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Rapid developments have occurred both in laboratory medicine and in therapeutic interventions for the management of patients with chronic myelogenous leukemia (CML). With a wide array of laboratory tests available, selecting the appropriate test for a specific diagnostic or therapeutic setting has become increasingly difficult. In this review, we first discuss, from the point of view of laboratory medicine, the advantages and disadvantages of several commonly used laboratory assays, including cytogenetics, fluorescence in situ hybridization (FISH), and qualitative and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). We then discuss, from the point of view of clinical care, the test(s) of choice for the most common clinical scenarios, including diagnosis and monitoring of the therapeutic response and minimal residual disease in patients treated with different therapies. The purpose of this review is to help clinicians and laboratory physicians select appropriate tests for the diagnosis and monitoring of CML, with the ultimate goal of improving the cost effective usage of clinical laboratories and improving patient care.

Original languageEnglish (US)
Pages (from-to)97-111
Number of pages15
JournalGenes Chromosomes and Cancer
Volume32
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Clinical Laboratory Techniques
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Medicine
Residual Neoplasm
Therapeutics
Reverse Transcriptase Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Cytogenetics
Patient Care
Physicians
Costs and Cost Analysis

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Chronic myelogenous leukemia : Laboratory diagnosis and monitoring. / Lynn Wang, Y.; Bagg, A.; Pear, Warren; Nowell, Peter C.; Hess, Jay.

In: Genes Chromosomes and Cancer, Vol. 32, No. 2, 2001, p. 97-111.

Research output: Contribution to journalArticle

Lynn Wang, Y. ; Bagg, A. ; Pear, Warren ; Nowell, Peter C. ; Hess, Jay. / Chronic myelogenous leukemia : Laboratory diagnosis and monitoring. In: Genes Chromosomes and Cancer. 2001 ; Vol. 32, No. 2. pp. 97-111.
@article{ad4871e235164c69885b2589a0048e4b,
title = "Chronic myelogenous leukemia: Laboratory diagnosis and monitoring",
abstract = "Rapid developments have occurred both in laboratory medicine and in therapeutic interventions for the management of patients with chronic myelogenous leukemia (CML). With a wide array of laboratory tests available, selecting the appropriate test for a specific diagnostic or therapeutic setting has become increasingly difficult. In this review, we first discuss, from the point of view of laboratory medicine, the advantages and disadvantages of several commonly used laboratory assays, including cytogenetics, fluorescence in situ hybridization (FISH), and qualitative and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). We then discuss, from the point of view of clinical care, the test(s) of choice for the most common clinical scenarios, including diagnosis and monitoring of the therapeutic response and minimal residual disease in patients treated with different therapies. The purpose of this review is to help clinicians and laboratory physicians select appropriate tests for the diagnosis and monitoring of CML, with the ultimate goal of improving the cost effective usage of clinical laboratories and improving patient care.",
author = "{Lynn Wang}, Y. and A. Bagg and Warren Pear and Nowell, {Peter C.} and Jay Hess",
year = "2001",
doi = "10.1002/gcc.1171",
language = "English (US)",
volume = "32",
pages = "97--111",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Chronic myelogenous leukemia

T2 - Laboratory diagnosis and monitoring

AU - Lynn Wang, Y.

AU - Bagg, A.

AU - Pear, Warren

AU - Nowell, Peter C.

AU - Hess, Jay

PY - 2001

Y1 - 2001

N2 - Rapid developments have occurred both in laboratory medicine and in therapeutic interventions for the management of patients with chronic myelogenous leukemia (CML). With a wide array of laboratory tests available, selecting the appropriate test for a specific diagnostic or therapeutic setting has become increasingly difficult. In this review, we first discuss, from the point of view of laboratory medicine, the advantages and disadvantages of several commonly used laboratory assays, including cytogenetics, fluorescence in situ hybridization (FISH), and qualitative and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). We then discuss, from the point of view of clinical care, the test(s) of choice for the most common clinical scenarios, including diagnosis and monitoring of the therapeutic response and minimal residual disease in patients treated with different therapies. The purpose of this review is to help clinicians and laboratory physicians select appropriate tests for the diagnosis and monitoring of CML, with the ultimate goal of improving the cost effective usage of clinical laboratories and improving patient care.

AB - Rapid developments have occurred both in laboratory medicine and in therapeutic interventions for the management of patients with chronic myelogenous leukemia (CML). With a wide array of laboratory tests available, selecting the appropriate test for a specific diagnostic or therapeutic setting has become increasingly difficult. In this review, we first discuss, from the point of view of laboratory medicine, the advantages and disadvantages of several commonly used laboratory assays, including cytogenetics, fluorescence in situ hybridization (FISH), and qualitative and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). We then discuss, from the point of view of clinical care, the test(s) of choice for the most common clinical scenarios, including diagnosis and monitoring of the therapeutic response and minimal residual disease in patients treated with different therapies. The purpose of this review is to help clinicians and laboratory physicians select appropriate tests for the diagnosis and monitoring of CML, with the ultimate goal of improving the cost effective usage of clinical laboratories and improving patient care.

UR - http://www.scopus.com/inward/record.url?scp=0034842032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034842032&partnerID=8YFLogxK

U2 - 10.1002/gcc.1171

DO - 10.1002/gcc.1171

M3 - Article

VL - 32

SP - 97

EP - 111

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 2

ER -